is an indicator of future risk of osteoporosis. Up to 1-3% of cortical bone and 5% of trabecular bone is lost per year after The effectiveness of hormone replacement therapy (HRT) menopause. Women lose up to 50% of trabecular bone and and alendronate, alone and in combination, was evaluated 35% of cortical bone mass in their life time (Riggs et al., in 120 postmenopausal patients with osteoporosis with bone 1981). Vertebral crush fractures are seen in 25% of postmineral density (BMD) measurements at least 2 SD below menopausal women after 70 years of age. The life-time risk the mean value for young premenopausal subjects. They of hip fracture in women is 15% and rises to 35% at the age had no contra-indications to HRT or alendronate use and of 90 years. These fractures are associated with a high level were randomized to three different treatment groups.
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of morbidity and the overall mortality rate has been reported Group I was treated with micronized 17β-oestradiol 2 mg to be 20% (Genant et al., 1989) . and norethisterone acetate 1 mg/day per os, group II Bone mineral density (BMD) measurements reflect bone received alendronate 10 mg/day per os and group III mass and fracture risk. For a woman whose femoral neck received micronized 17β-oestradiol 2 mg, norethisterone BMD is 1 SD lower than the mean value for her age group, acetate 1 mg/day per os and alendronate 10 mg/day per os the risk of hip fracture is almost seven times higher compared for 1 year. Elementary calcium 1500 mg/day was supplied with a woman whose femoral neck BMD is 1 SD higher than to patients in all three groups. Spinal and femoral neck the mean (Cummings et al., 1990) .
BMD and markers of bone mineral metabolism were
Since the early 1970s, several studies have proved that measured on each patient before treatment and 6 and 12 hormone replacement therapy (HRT) reduces bone loss. HRT months after treatment in 95 patients. At the end of the stabilizes bone turnover and has been claimed to decrease hip 12th month, significant increases in spinal and femoral fractures by nearly 50-60% (Kiel et al., 1987) . The major neck BMD were found in all groups. Increases in spinal drawback of HRT is discontinuation or complete refusal of BMD were significantly higher in patients treated with the treatment owing to side-effects such as abnormal uterine alendronate and alendronate with HRT when compared bleeding, oedema and breast tenderness and a fear of developing with patients treated with HRT only. No significant differcancer. For long-term preservation of BMD, women should ence was found in femoral neck BMD changes between take oestrogen for at least 7 years after menopause and even the groups. Significant decreases in bone resorption and this duration of therapy may have little residual effect on bone markers of bone formation were observed in all groups.
density among women 75 years of age and older, who have Alendronate was found to be more effective than HRT and the highest risk of fracture (Felson et al., 1993) . could have a very beneficial effect when added to the HRT A variety of agents is now being used for the management regimen in patients with postmenopausal osteoporosis.
of postmenopausal osteoporosis. Vitamin D analogues, sodium Alendronate might also be used in postmenopausal patients fluoride, calcitonin, selective oestrogen receptor modulators with osteoporosis when HRT is contra-indicated or when (SERM) and bisphosphonates may be used when HRT is there is reluctance to use hormonal treatment.
contra-indicated or not acceptable by the patient (Meunier Key words: alendronate/bone mineral density/hormone replaceet al., 1999) and if proven effective may be alternatives to ment therapy/menopause/osteoporosis HRT. But it should be emphasized that they lack the beneficial effects of HRT on the cardiovascular system, genito-urinary tract and mental status. Alendronate; a new bisphosphonate, Introduction whose exact mechanism of action is still controversial, has been shown to be beneficial in patients with postmenopausal Osteoporosis typically affects women within the first 15 years after menopause, and is characterized mostly by loss of osteoporosis (Jeal et al., 1997) .
The objective of the present study was to identify changes trabecular bone (Riggs and Melton, 1990 HRT is administered to women with osteoporosis.
Measurements
Institutional Review Board approval was obtained and patients were
Materials and methods
informed and written consents were obtained. A total of 120 patients who met the inclusion criteria were randomized into one of three Protocol treatment groups using a blocked randomization method with a Women attending the menopause clinic of Gazi University School of blocking factor of 5. Medicine, Department of Obstetrics and Gynecology between January BMD measurements were performed with DEXA using a Norland and November 1997 and who were found to have low BMD values, XR-36 Bone Densitometer (Norland Corp., Fort Atkinson, WI, USA). i.e. at least 2 SD below normal, were eligible for the study.
A standard mode setting of 60 mm/s was used. In our laboratory, the At the initial visit, general physical and pelvic examinations were coefficient of variation for replicate measurements at the lumbar spine performed and a Pap smear was taken. Baseline laboratory tests and femoral neck was~1.5%. were performed for measurement of serum FSH, LH, oestradiol
Osteocalcin concentrations were measured with DSL-6900 radioconcentrations, a complete blood count and liver and renal function immunoassay kits from DSL with a sensitivity of 0.6 ng/ml and intra tests. Pelvic ultrasonography and bilateral mammography were also and interassay coefficients of variation (CV) of 7.4 and 6.7% performed. To document osteoporosis, lumbar and femoral neck BMD respectively (Diagnostic Systems Laboratories Inc., Webster, TX, measurements were performed. Serum parathormone, osteocalcin, USA). Parathormone concentrations were measured with DSL-8000 alkaline phosphatase, calcium, phosphorus and morning urinary radioimmunoassay kits from DSL with a sensitivity of 12 pg/ml and calcium excretion were measured for each patient.
intra-and inter-assay CV of 5.7 and 4.5% respectively. Serum and The inclusion criteria for the study were: (i) at least 1 year of urinary calcium concentrations were measured spectrophotometrically amenorrhoea, serum FSH concentrations Ͼ40 IU/l and serum oestrawith DAX Technicon 48 (Bayer Corporation, Tarrytown, New York, diol concentrations Ͼ40 pg/ml (only natural menopausal women with USA), using O-cresolphthalein complexone. Serum phosphate concenintact ovaries); (ii) lumbar L2-L4 BMD at least 2 SD below the mean trations were measured spectrophotometrically with DAX Technicon peak values for young premenopausal women [measured with dual 48 using ammonium hepta molibdate. Serum alkaline phosphatase energy X-ray absorptiometry (DEXA), T score Ͻ-2] where T score concentrations were measured spectrophotometrically with DAX is the difference between the mean peak bone density values for Technicon 48 using American Associated Clinical Chemistry (AACC) young premenopausal women and the measured subjects; (iii) not and International Federation of Clinical Chemistry (IFCC) methods. using HRT or any agent affecting bone turnover in the previous year;
Urinary creatinine concentrations were measured spectrophotometr-(iv) no metabolic disease that alters bone metabolism or systemic ically with DAX Technicon 48 using Taffe reaction. disease affecting general health status; (v) no evidence of malignancy associated with oestrogen use (e.g. endometrial or breast cancer); (vi) Statistical analysis no contra-indications for HRT use, such as undiagnosed uterine
The results are expressed as the mean Ϯ SD for age, BMI, time since bleeding, active liver disease or thrombo-embolic disease; (vii) body menopause, BMD and bone turnover markers. Changes from baseline mass index (BMI) Ͻ30 kg/m 2 ; (viii) no active upper gastro-intestinal lumbar and femoral neck BMD measurements are expressed as mean disease or calcium urolithiasis; (ix) no vertebral deformity that may Ϯ SEM. Multiple group comparisons for percentage changes in BMD affect measurement of BMD. from baseline were made at 6 and 12 months of follow-up by oneThe study groups were planned as follows: group I (n ϭ 40):
way analysis of variance (ANOVA). Between-group differences were micronized 17β-oestradiol 2.0 mg Ϯ norethisterone acetate 1.0 mg/ assessed by Bonferroni's post-hoc test. Changes from baseline in day per os (Kliogest tablet; Novo Nordisk, Bagsvaerd, Denmark); biochemical variables and bone mass measurements were evaluated group II (n ϭ 40): alendronate-Na 10 mg/day per os (Fosamax tablet by paired t-test. 10 mg; Merck & Co., Inc., Whitehouse Station, NJ, USA); group III (n ϭ 40): micronized 17β-oestradiol 2.0 mg Ϯ norethisterone acetate 1.0 mg/day per os (Kliogest tablet; Novo Nordisk) ϩ alendronate-
Results
Na 10 mg/day per os (Fosamax tablet 10 mg; Merck & Co., Inc.).
Participant flow and follow-up
Elementary calcium 1500 mg/day per os (Ca Sandoz effervescent tablet 1500 mg; Novartis Pharma AG, Basel, Switzerland) was added Out of the 120 patients who began the study, four were to each treatment regimen. discharged owing to side-effects and 21 were excluded because The total treatment period was planned to be 12 months and of non-compliance with the study. Thus, analysis was perpatients were examined every 6 months. At each visit, general formed on 95 subjects who completed the follow-up period to physical examination was performed and patients questioned about the end of the 12th month. Group I (HRT) had 31, group II adverse effects. Lumbar and femoral neck BMD measurements (alendronate) 32 and group III (HRT ϩ alendronate) 32 and serum concentrations of parathormone, osteocalcin, alkaline subjects ( Figure 1) . phosphatase, calcium, phosphorus and urinary calcium excretion were planned to be measured.
Analysis
For patients treated with HRT, the presence of venous thromboClinical features of the patients are shown in Table I . There embolic disease, jaundice, severe headache, uncontrolled hypertension, abnormalities in liver function tests and irregular or heavy were no significant differences between the groups when age, Femoral neck BMD measurements increased 4.57 Ϯ 0.97% in group III at the end of the 12th month and this was the highest increase among the groups. There were no significant differences between the groups for the percentage changes in femoral neck BMD measurements (Figure 3) . No significant differences were present between the groups for baseline alkaline phosphatase and osteocalcin concentrations (Table III) . Declining alkaline phosphatase measurements were observed in all groups. The decrease in osteocalcin concentrations was significant for all groups both at 6 and 12 months except for group I at the 6 months. Baseline calcium and phosphorus concentrations were not different between the groups. Both calcium and phosphorus measurements revealed a non-significant decrease in group I over the study period but the differences for groups II and III were statistically significant. Phosphorus concentrations were significantly different at 6 months between groups I and III (Bonferroni's post-hoc test). There were no differences in baseline parathormone concentrations and urinary calcium/creatinine (urinary calcium urements increased significantly at 6 months for groups II and group II: alendronate; group III: HRT ϩ alendronate.
III. At 12 months there were decreases in parathormone concentrations in these two groups compared with the 6th month but this was only significant in group II (P Ͻ 0.005). excluded at the third and fourth months respectively because There were no significant differences between the groups. LMP ϭ last menstrual period.
of severe epigastric pain which in one of them was due to oesophagitis. Another two patients, one each from groups I and III, were withdrawn due to irregular, long-lasting heavy time since last menstrual period and BMI were considered (Table I) .
uterine bleeding. Endometrial biopsy demonstrated proliferative endometrium in both of them. There were no differences in baseline vertebral and femoral neck BMD measurements and all were at least 2 SD below the mean peak BMD measurements in young premenopausal Discussion subjects (T score Ͻ-2).
Both at the 6 and 12 month periods, the mean vertebral and There are several alternatives for the prevention and treatment of osteoporosis, HRT being the most commonly used regimen femoral neck BMD measurements were significantly higher compared to baseline. However, no significant differences in because of its documented effectiveness on bone mass and other beneficial effects during postmenopausal years (Reid., 1999) . mean BMD measurements were seen between the groups at 6 and 12 months (Table II) .
In the present study, we found a 2.63 Ϯ 0.63% increase in vertebral BMD and 3.21 Ϯ 0.56% increase in femoral neck When evaluating the percentage changes from baseline L2-L4 vertebral BMD measurements, the highest increase was BMD at the end of the 12th month in patients managed with HRT. These increases were statistically significant and confirm observed in group III (8.41 Ϯ 0.94%) at the end of the 12th month. This increase was 2.63 Ϯ 0.63% for group I.
that HRT not only prevents more bone loss but can also increase BMD. Some authors claim that HRT cannot restore Percentage changes from baseline in lumbar BMD measurements were significantly different between the groups both at the lost bone mass (Renzo et al., 1994) but others report HRT to increase bone mass regardless of the time that has passed 6 and 12 months. When analysed with the post-hoc test of Bonferroni, this difference was found to be higher between after menopause (Quigley et al., 1987) . HRT been found to increase vertebral BMD by 10% and groups I and II, and I and III. In other words, BMD measurements increased more in patients in groups II and III compared femoral neck BMD by 5.5% at the end of a 3 year treatment period (Lindsay and Tohme, 1990) . HRT was reported to to patients in group I (Figure 2) . vertebral BMD after 1 year of treatment was found to increase 2.5% in the HRT group and to decrease 4.9% in those receiving placebo (Ettinger et al., 1992) . Alendronate is a new bisphosphonate that has been used in managing postmenopausal osteoporosis and has been found to have a beneficial effect on BMD, reducing the risk of fractures (Jeal et al., 1997) . In the present study, 7.23 Ϯ 0.67% increase in vertebral and 3.02 Ϯ 0.44 % increase in femoral neck BMD measurements at the end of the 12th month were consistent with the findings in the literature. An important point is that with different doses of alendronate for 3 years, a 10 mg/day dose increased vertebral and femoral neck BMD measurements 9.6 and 4.7% respectively and these increases were not different in the group treated with 20 mg/day (Tucci et al., 1996) . We have also used alendronate at a dose of 10 mg/day.
It has been reported that the increases in BMD were highest in the first year of the treatment period in patients using alendronate. This accelerated increase is thought to be due to decrease in bone turnover and mineralization of the present bone remodelling units (Heaney, 1994) . Although maximal effects of alendronate are seen in the first 6-12 months, increases in BMD have also been reported in the second or (Jeal et al., 1997) . At the end of 3 years, Devogelaer (BMD) from baseline. *Group I: hormone replacement therapy (HRT); group II: alendronate; group III: HRT ϩ alendronate. and co-workers found that alendronate had increased vertebral It has also been reported that the incidence of new fracture Ϯ 0.907 and 4.575 Ϯ 0.979. risk was 3.2% in patients treated with alendronate compared to 6.2% in those taking placebo at the end of the 3 years. decrease hip and distal forearm fractures by 50-60% and They concluded that alendronate decreases fractures by 48% vertebral fractures by 70-80% after long-term treatment (Weiss (Liberman et al., 1995 (Liberman et al., ). et al., 1980 Ettinger et al., 1985; Genant et al., 1989) .
Furthermore, women with increases of ജ3% in BMD during The combination of 17β-oestradiol 2.0 mg ϩ norethisterone the first 1 or 2 years of alendronate treatment were found to acetate 1.0 mg/day used in this study has been documented to have the lowest incidence of new vertebral fractures, suggesting be effective in osteoporotic patients. Of 63 osteoporotic patients included in a clinical trial using this HRT regimen or placebo, that, among women taking anti-resorptive agents, greater 
